Ascendis Pharma As Stock Current Valuation
| A1SN34 Stock | BRL 56.10 0.00 0.00% |
Valuation analysis of Ascendis Pharma AS helps investors to measure Ascendis Pharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Fairly Valued
Today
Please note that Ascendis Pharma's price fluctuation is very steady at this time. Calculation of the real value of Ascendis Pharma AS is based on 3 months time horizon. Increasing Ascendis Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Ascendis Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Ascendis Stock. However, Ascendis Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 56.1 | Real 56.0 | Hype 56.1 | Naive 56.4 |
The real value of Ascendis Stock, also known as its intrinsic value, is the underlying worth of Ascendis Pharma AS Company, which is reflected in its stock price. It is based on Ascendis Pharma's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Ascendis Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Ascendis Pharma AS helps investors to forecast how Ascendis stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Ascendis Pharma more accurately as focusing exclusively on Ascendis Pharma's fundamentals will not take into account other important factors: Ascendis Pharma AS Company Current Valuation Analysis
Ascendis Pharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Ascendis Pharma Current Valuation | 34.82 B |
Most of Ascendis Pharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ascendis Pharma AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Ascendis Pharma AS has a Current Valuation of 34.82 B. This is 142.46% higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The current valuation for all Brazil stocks is 109.48% lower than that of the firm.
Ascendis Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ascendis Pharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ascendis Pharma could also be used in its relative valuation, which is a method of valuing Ascendis Pharma by comparing valuation metrics of similar companies.Ascendis Pharma is currently under evaluation in current valuation category among its peers.
Ascendis Fundamentals
| Return On Equity | -0.67 | |||
| Return On Asset | -0.27 | |||
| Operating Margin | (15.89) % | |||
| Current Valuation | 34.82 B | |||
| Shares Outstanding | 57.03 M | |||
| Price To Book | 0.90 X | |||
| Price To Sales | 1,080 X | |||
| Revenue | 7.78 M | |||
| Gross Profit | 4.25 M | |||
| EBITDA | (364.64 M) | |||
| Net Income | (383.58 M) | |||
| Book Value Per Share | 8.08 X | |||
| Cash Flow From Operations | (417.65 M) | |||
| Number Of Employees | 639 | |||
| Beta | 0.47 | |||
| Market Capitalization | 34.39 B | |||
| Total Asset | 1.08 B | |||
| Net Asset | 1.08 B |
About Ascendis Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ascendis Pharma AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ascendis Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ascendis Pharma AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Information and Resources on Investing in Ascendis Stock
When determining whether Ascendis Pharma AS is a strong investment it is important to analyze Ascendis Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascendis Pharma's future performance. For an informed investment choice regarding Ascendis Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ascendis Pharma AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.